New allergy shot for teens shows early promise
NCT ID NCT07148557
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new injection called LP-003 in 6 teenagers aged 12 to 18 who have allergies like hay fever, asthma, or eczema. The main goal is to check if the drug is safe and how the body processes it. This is an early-stage trial, so it focuses on safety and drug levels rather than how well it treats symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Early-Life factors steer preterm and term infant health?
- New allergy shot for teens enters early safety testing
- Probiotic cocktail may shield Antibiotic-Exposed infants from allergies
- Pregnancy diet study tracks moms and kids for five years
- EATING YOUR WAY TO CLEARER SKIN? NEW STUDY TESTS DIET FOR ECZEMA
- Massive study tracks 2500 kids from womb to uncover allergy roots